Skip to main content

Table 1 Cohort demographics and disease characteristics

From: Visualization of atherosclerosis as detected by coronary artery calcium and carotid intima-media thickness reveals significant atherosclerosis in a cross-sectional study of psoriasis patients in a tertiary care center

Demographics

Psoriasis (N = 207)

Controls (N = 76)

p-value

Mean ± SEM or N (%)

Mean ± SEM or N (%)

Age (years)

47.8 ± 1.0

48.8 ± 2.0

0.651

Gender (male)

114 (55.1 %)

40 (52.6 %)

0.715

Race (not Caucasian)

24 (11.6 %)

9 (11.8 %)

0.954

Characteristics of interest

BMI (kg/m2)

30.9 ± 0.5

28.9 ± 0.1

0.025

Current smoker

78 (37.7 %)

14 (18.4 %)

0.002

Dyslipidemia

110 (53.1 %)

28 (36.8 %)

0.022

Systolic blood pressure

131 ± 1.3

123 ± 2.2

0.002

Fasting blood glucose (mg/dL)

94.7 ± 1.7

91.6 ± 1.4

0.184

HDL (mg/dL)

51.1 ± 1.0

55.9 ± 1.5

0.009

Hypertension

95 (45.9 %)

19 (25.0 %)

0.001

hsCRP

5.6 ± 0.7

3.3 ± 1.0

0.003

LDL (mg/dL)

121.2 ± 2.5

110.4 ± 3.9

0.027

Statin therapy

44 (21.3 %)

16 (21.1 %)

0.97

Total cholesterol (mg/dL)

197.4 ± 3.0

188.9 ± 4.7

0.128

Triglyceride (mg/dL)

125.9 ± 5.4

115.2 ± 11.3

0.392

Waist circumference (in)

40.2 ± 0.5

38.4 ± 0.6

0.028

Coronary artery calcium (CAC)

159 ± 32

130 ± 52

0.649

10 year Framingham risk score

5.8 ± 0.4

4.8 ± 0.8

0.235

Psoriasis specific

BSA

14.3 ± 1.3

N/A

ND

PASI

10 ± 0.7

N/A

ND

PGA

2.2 ± 0.1

N/A

ND

Psoriasis arthritis

51 (24.6 %)

N/A

ND

Psoriasis duration (years)

19.4 ± 1.0

N/A

ND

Psoriasis treatment(s)

Biologics

49 (23.7 %)

N/A

ND

Cyclosporine

5 (2.4 %)

N/A

ND

Methotrexate

13 (6.3 %)

N/A

ND

Narrow band UVB

13 (6.3 %)

N/A

ND

Oral retinoids

7 (3.4 %)

N/A

ND

Topicals

96 (46.4 %)

N/A

ND